Excellent biotechnology news in 2022? BioTech Health X brings you the latest quality biotech news including breaking news on the latest biotechnology research, emerging companies, biotech acquisitions, funding deals and other industry analysis. BioTech Health X coverage includes a wide range of life sciences industry research including therapeutics, Pharma, cell therapy, others. Companies & researchers in the biotechnology business focus on developing drugs that could help to cure disease like cancer, DNA, Alzheimer’s and other medical related and genetic conditions. New cell therapies and modern research technologies have been developed allowing a company in the space to gather new data through trial research as they search for what could be the cure.
The product is a medical device used with the aim of facilitating regeneration and reconstructing functions of peripheral nerves severed or lost due to external injury. The device is a tube made of polyglycolic acid filled with sponge-shaped collagen, which enables the creation of an environment to induce nerve growth and reconstruct the severed section. The sponge-like structure of collagen has been confirmed as effective in multiplying nerve cells. The nerve conduit products made of synthesized materials that are available on the overseas market have reportedly caused some instances of triggering inflammatory reactions when the materials have decomposed inside the body*4. However, such events were not found with Nerbridge TM in a systematic literature search Toyobo has been making for the past several years in Japan. Using Nerbridge TM makes it unnecessary to harvest healthy peripheral nerves for autografting, reducing the patient’s burden and shortening the time needed for surgical treatment.
Miller shared that CureDuchenne provided early funding to a large percentage of companies in the DMD space that are now in the clinical trial stage. Our vision is our name: to cure Duchenne, she said. Our goal is to uncover, fund and de-risk early science. By finding the technology that’s most likely to work for Duchenne, the company is filling the therapeutic pipeline. Miller makes a point to sit in on the Department of Defense’s Congressionally Directed Medical Research Programs, and stated that CureDuchenne is the largest funder of DMD research outside of the federal government. She described the softer side of the company, outlining its commitment to providing community support. One thing that is really important to us is providing hope to the families. We do that by highlighting and celebrating things that our young men with Duchenne can do. We focus on their accomplishments and how they’re continually raising the bar in terms of their achievements.
Our coverage spans research at the university level to Leibniz Institute Sagol Center to Hans Knöll Institute, infection biology to children with rare gene diseases, to the latest new infection that may arise like the risk of a global virus BioTech Health X keeps you up to date with news as it is revealed. Our team helps describe and characterize the new method of treatments like the promising nature of the COVID 19 vaccine. Breakthrough drugs are being made by various research team around the world and the environment in which we live is ever changing. See more information at biotechhealthx.com.
In terms of regional segmentation, the global passive prosthetics market is divided into five key regions namely Asia Pacific, Europe, Latin America, North America, and the Middle East and Africa. Currently, the North America market is the leading regional segment. The growth of the market is due to the growing awareness about passive prosthetics among the people. Moreover, the early access to the new technologies and products in the market are also helping the passive prosthetics market grow in the region. Other region such as the Middle East and Africa and Europe are showing steady growth of the market in recent years.